The European Huntington Association recently spoke with Dr Ralf Reilmann about the Select-HD trial, which is investigating the safety and tolerability of WVE-003 in people with HD. Below is a summary of the trial.
SELECT-HD
Who runs this study? Wave Life Sciences
What’s its current status? Active and recruiting.
Where is it running? Australia, Canada, Denmark, France, Germany, Italy, Poland, Spain, United Kingdom
Who’s potentially eligible? Adults aged 25 to 60 years with HD.
What are they investigating? This Phase Ib/IIa trial is investigating the safety and tolerability of WVE-003 in people with HD. WVE-003 is a drug designed to lower the toxic form of the huntingtin protein, delivered intrathecally (into the CSF through the spine). WVE-003 targets a specific genetic signature, which not every person with HD has, so if successful this drug would only be able to treat a subset of people with HD.